OncoMatch/Clinical Trials/NCT06561074
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Is NCT06561074 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Decitabine and Venetoclax for t-cell acute lymphoblastic leukemia.
Treatment: Decitabine · Venetoclax · Calaspargase pegol-mknl — To learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy. The safety of this drug combination will also be studied.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG/LANSKY 0–2
ECOG ≤2 for patients≥16 years old, Lansky score >50 for patients<16 years old
Lab requirements
Kidney function
creatinine clearance ≥ 30 mL/min unless related to disease
Liver function
Total serum bilirubin ≤1.5 x ULN (≤3 x ULN if Gilbert's syndrome); ALT/AST ≤3 x ULN (≤5 x ULN if suspected leukemic liver involvement)
Total serum bilirubin ≤1.5 x ULN (≤3 x ULN if Gilbert's syndrome). Adequate renal function (creatinine clearance ≥ 30 mL/min) unless related to disease. ALT/AST ≤3 x ULN; ≤5 x ULN unless in case of suspected leukemic liver involvement. Amylase, Lipase and Triglycerides must be WNL prior to administration of calaspargase pegol-mknl.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify